What is HC Wainwright’s Estimate for AGIO Q3 Earnings?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Equities researchers at HC Wainwright issued their Q3 2026 earnings per share estimates for Agios Pharmaceuticals in a research report issued on Thursday, October 29th. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company will post earnings of ($1.26) per share for the quarter. HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($5.85) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q4 2026 earnings at ($1.42) EPS, FY2026 earnings at ($6.05) EPS, FY2027 earnings at ($4.61) EPS, FY2028 earnings at ($2.92) EPS, FY2029 earnings at ($1.61) EPS and FY2030 earnings at $0.72 EPS.

AGIO has been the topic of a number of other research reports. TD Cowen upgraded shares of Agios Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 24th. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, September 21st. Citigroup lifted their price target on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Bank of America upped their price objective on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a “buy” rating in a report on Monday, September 21st. Finally, Royal Bank Of Canada increased their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Agios Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $41.50.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $29.95 on Monday. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -4.27 and a beta of 0.63. Agios Pharmaceuticals has a 52-week low of $22.24 and a 52-week high of $46.00. The stock’s 50 day moving average price is $33.56 and its two-hundred day moving average price is $31.71.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 7,866 shares of the stock in a transaction on Monday, October 26th. The stock was sold at an average price of $37.69, for a total value of $296,469.54. Following the transaction, the insider directly owned 54,645 shares in the company, valued at $2,059,570.05. This trade represents a 12.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 9,855 shares of company stock worth $371,112 over the last quarter. 5.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AGIO. BlackRock Inc. acquired a new position in shares of Agios Pharmaceuticals during the second quarter valued at about $239,582,000. Assenagon Asset Management S.A. raised its holdings in shares of Agios Pharmaceuticals by 1,714.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock worth $62,723,000 after acquiring an additional 1,782,457 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter worth approximately $47,800,000. Dimensional Fund Advisors LP increased its holdings in Agios Pharmaceuticals by 14.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,151,614 shares of the biopharmaceutical company’s stock worth $38,940,000 after purchasing an additional 147,273 shares in the last quarter. Finally, Parkman Healthcare Partners LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter worth approximately $24,828,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.